Interim report January–June 2025: Weak sales and significant currency effects weighed on the result

Summary by AI ^BETAClose X

Surgical Science Sweden AB (publ) reported a net sales decrease of 2 percent to SEK 209.2 million in the second quarter of 2025, compared to SEK 212.5 million in the same period of the previous year. Excluding Intelligent Ultrasound sales of SEK 22.1 million, comparable unit sales decreased by 12 percent. License revenue decreased to SEK 58.9 million (28 percent of net sales) from SEK 67.1 million (32 percent). The gross margin was 65 percent, down from 68 percent. The operating result was a loss of SEK -22.4 million, impacted by negative currency effects of SEK 24.7 million, compared to an operating profit of SEK 33.4 million in Q2 2024. The net result was a loss of SEK -20.1 million, or SEK -0.39 earnings per share, compared to a net profit of SEK 28.6 million and SEK 0.56 earnings per share in the prior-year period. Cash flow from operating activities was SEK 16.2 million (SEK 30.0 million in Q2 2024), and cash and cash equivalents totaled SEK 610.2 million as of June 30, 2025. For the first half of 2025, net sales increased by 15 percent to SEK 459.8 million, with comparable unit sales up 5 percent. License revenue was SEK 142.7 million (31 percent of net sales), and the gross margin remained at 67 percent. The operating profit was SEK 1.5 million, significantly lower than the SEK 59.4 million in H1 2024, due to SEK 22.6 million in acquisition costs and SEK 3.9 million in restructuring costs related to the Intelligent Ultrasound acquisition. Net profit was SEK 13.2 million, or SEK 0.26 earnings per share, versus SEK 52.4 million and SEK 1.03 earnings per share in the first half of 2024. Cash flow from operating activities for the first half of 2025 amounted to SEK 11.3 million.

Disclaimer*

Second quarter 2025 (April–June)

Net sales amounted to SEK 209.2 (212.5) million, a decrease of 2 percent compared with the corresponding period in the preceding year. Delays in order placement meant that the order book for simulators was approximately SEK 30 million larger at the end of the quarter than at the beginning.
Sales of SEK 22.1 million from Intelligent Ultrasound are included in the figures. For comparable units, sales decreased by 12 percent.
License revenue amounted to SEK 58.9 (67.1) million and accounted for 28 (32) percent of net sales.
The gross margin was 65 (68) percent.
Operating result amounted to SEK -22.4 (33.4) million. Operating result includes negative currency effects in Other operating income and expenses of SEK 24.7 million.
Net result amounted to SEK -20.1 (28.6) million, corresponding to earnings per share of SEK -0.39 (0.56).
Cash flow from operating activities amounted to SEK 16.2 (30.0) million. As of June 30, 2025, cash and cash equivalents amounted to SEK 610.2 million (667.1).

First half of 2025 (January–June)

Net sales amounted to SEK 459.8 (400.7) million, an increase of 15 percent compared with the corresponding period in the preceding year.
For comparable units, sales increased by 5 percent.
License revenue amounted to SEK 142.7 (130.3) million and accounted for 31 (33) percent of net sales.
The gross margin was 67 (67) percent.
Operating profit amounted to SEK 1.5 (59.4) million. Profit includes SEK 22.6 million in acquisition costs and SEK 3.9 million in restructuring costs, both of which are attributable to the acquisition of Intelligent Ultrasound.
Net profit amounted to SEK 13.2 (52.4) million, corresponding to earnings per share of SEK 0.26 (1.03).
Cash flow from operating activities amounted to SEK 11.3 (58.5) million.
Intelligent Ultrasound, which operates in the field of ultrasound simulation, was acquired in February. The acquisition date was February 18.

Gothenburg, Sweden, August 21, 2025
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

About Surgical Science Sweden AB (publ)

One of the biggest challenges within healthcare globally is reducing injuries incurred during care. Medical education and training are key, especially as a large part of the training can now be performed outside the operating room. Surgical Science is a world leader in the development of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psycho-motor skills and instrument handling before entering the clinical environment. Alongside its own products, Surgical Science works with simulation solutions for medical device companies that develop instruments for clinical use, such as robotic surgery.

Surgical Science has approximately 330 employees. The company is headquartered in Gothenburg, Sweden, and has operations in Tel Aviv, Israel; Stockholm, Sweden; Seattle and Cleveland, US; and Cardiff, UK. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market. Certified Adviser is DNB Carnegie Investment Bank AB.